Exact Sciences Corporation
EXAS
Rank in Stocks
#1149
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Share Price
$104.91
Last synced: 2026-03-23
Market Cap
$20.03B
Change (1 day)
0.00%
Change (1 year)
71.34%
Country
US
Trade Exact Sciences Corporation (EXAS)
Category
Healthcare
P/S ratio for Exact Sciences Corporation (EXAS)
P/S ratio as of October 2026 TTM: 7.88
According to Exact Sciences Corporation latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.88. At the end of 2023 the company had a P/S ratio of 5.33.
P/S ratio history for Exact Sciences Corporation from 2000 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 7.88 | 110.23% |
| 2024 | 3.75 | -29.63% |
| 2023 | 5.33 | 27.27% |
| 2022 | 4.19 | -44.49% |
| 2021 | 7.55 | -43.79% |
| 2020 | 13.43 | -3.07% |
| 2019 | 13.85 | -18.36% |
| 2018 | 16.97 | -25.74% |
| 2017 | 22.85 | 66.09% |
| 2016 | 13.76 | -36.20% |
| 2015 | 21.56 | -98.24% |
| 2014 | 1.22K | 539.83% |
| 2013 | 191.37 | 25.90% |
| 2012 | 152.00 | 48.40% |
| 2011 | 102.43 | 126.26% |
| 2010 | 45.27 | 93.77% |
| 2009 | 23.36 | -230.59% |
| 2008 | -17.89 | -160.52% |
| 2007 | 29.56 | 87.17% |
| 2006 | 15.79 | 15.62% |
| 2005 | 13.66 | -30.52% |
| 2004 | 19.66 | -70.20% |
| 2003 | 65.97 | -70.36% |
| 2002 | 222.55 | -93.31% |
| 2001 | 3.33K | 0.00% |
| 2000 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 5.37 | -31.86% |
US
|
|
| 6.29 | -20.19% |
US
|
|
| 21.02 | 166.62% |
US
|
|
| - | - |
CN
|
|
| 6.67 | -15.44% |
US
|
